Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.

Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, Tess DA, Varma MVS.

J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. doi: 10.1124/jpet.118.252049. Epub 2018 Aug 22.

PMID:
30135178
2.

Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation.

Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, Varma MVS.

Mol Pharm. 2018 Mar 5;15(3):1284-1295. doi: 10.1021/acs.molpharmaceut.7b01108. Epub 2018 Feb 20.

PMID:
29433307
3.

Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug.

Bi YA, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildhede A, Costales C, Rodrigues AD, Varma MVS.

J Pharmacol Exp Ther. 2018 Mar;364(3):390-398. doi: 10.1124/jpet.117.245951. Epub 2018 Jan 11.

PMID:
29326367
4.

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).

Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, Myers JS, Rosfjord E, Lucas J, Gerber HP, Loganzo F.

Mol Cancer Ther. 2018 Jan;17(1):243-253. doi: 10.1158/1535-7163.MCT-17-0403. Epub 2017 Oct 20.

PMID:
29054985
5.

Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.

Boehm M, Beaumont K, Jones R, Kalgutkar AS, Zhang L, Atkinson K, Bai G, Brown JA, Eng H, Goetz GH, Holder BR, Khunte B, Lazzaro S, Limberakis C, Ryu S, Shapiro MJ, Tylaska L, Yan J, Turner R, Leung SSF, Ramaseshan M, Price DA, Liras S, Jacobson MP, Earp DJ, Lokey RS, Mathiowetz AM, Menhaji-Klotz E.

J Med Chem. 2017 Dec 14;60(23):9653-9663. doi: 10.1021/acs.jmedchem.7b01028. Epub 2017 Oct 30.

6.

In vitro studies with two human organic anion transporters: OAT2 and OAT7.

Mathialagan S, Costales C, Tylaska L, Kimoto E, Vildhede A, Johnson J, Johnson N, Sarashina T, Hashizume K, Isringhausen CD, Vermeer LMM, Wolff AR, Rodrigues AD.

Xenobiotica. 2018 Oct;48(10):1037-1049. doi: 10.1080/00498254.2017.1384595. Epub 2017 Oct 13.

PMID:
28945155
7.

Feasibility of Singlet Analysis for Ligand Binding Assays: a Retrospective Examination of Data Generated Using the Gyrolab Platform.

Clark TH, Yates PD, Chunyk AG, Joyce AP, Wu A, Pop-Damkov P, Zhang Y, Dreher EA, Tylaska LA, Wentland JA, Pelletier KB, King LE, Ray CA.

AAPS J. 2016 Sep;18(5):1300-8. doi: 10.1208/s12248-016-9944-8. Epub 2016 Jul 11.

PMID:
27401185
8.

Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists.

Kuhn CF, Bazin M, Philippe L, Zhang J, Tylaska L, Miret J, Bauer PH.

Chem Biol Drug Des. 2007 Sep;70(3):268-72.

PMID:
17718722
9.

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Brown MF, Bahnck KB, Blumberg LC, Brissette WH, Burrell SA, Driscoll JP, Fedeles F, Fisher MB, Foti RS, Gladue RP, Guzman-Martinez A, Hayward MM, Lira PD, Lillie BM, Lu Y, Lundquist GD, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Roache JH, Shavnya A, Shepard RM, Trevena KA, Tylaska LA.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3109-12. Epub 2007 Mar 15.

PMID:
17383873
10.

The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice.

Gladue RP, Cole SH, Roach ML, Tylaska LA, Nelson RT, Shepard RM, McNeish JD, Ogborne KT, Neote KS.

J Immunol. 2006 Mar 1;176(5):3141-8.

11.

Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.

McColl SR, Mahalingam S, Staykova M, Tylaska LA, Fisher KE, Strick CA, Gladue RP, Neote KS, Willenborg DO.

Lab Invest. 2004 Nov;84(11):1418-29.

12.

Novel CCR1 antagonists with improved metabolic stability.

Brown MF, Avery M, Brissette WH, Chang JH, Colizza K, Conklyn M, DiRico AP, Gladue RP, Kath JC, Krueger SS, Lira PD, Lillie BM, Lundquist GD, Mairs EN, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Rossulek MI, Shepard RM, Sims J, Strelevitz TJ, Truesdell S, Tylaska LA, Yoon K, Zheng D.

Bioorg Med Chem Lett. 2004 May 3;14(9):2175-9.

PMID:
15081003
13.

Potent small molecule CCR1 antagonists.

Kath JC, Brissette WH, Brown MF, Conklyn M, DiRico AP, Dorff P, Gladue RP, Lillie BM, Lira PD, Mairs EN, Martin WH, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Stock IA, Tylaska LA, Zheng D.

Bioorg Med Chem Lett. 2004 May 3;14(9):2169-73.

PMID:
15081002
14.

The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.

Kath JC, DiRico AP, Gladue RP, Martin WH, McElroy EB, Stock IA, Tylaska LA, Zheng D.

Bioorg Med Chem Lett. 2004 May 3;14(9):2163-7.

PMID:
15081001
15.

CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.

Gladue RP, Tylaska LA, Brissette WH, Lira PD, Kath JC, Poss CS, Brown MF, Paradis TJ, Conklyn MJ, Ogborne KT, McGlynn MA, Lillie BM, DiRico AP, Mairs EN, McElroy EB, Martin WH, Stock IA, Shepard RM, Showell HJ, Neote K.

J Biol Chem. 2003 Oct 17;278(42):40473-80. Epub 2003 Aug 7.

16.

Ccr2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen.

Tylaska LA, Boring L, Weng W, Aiello R, Charo IF, Rollins BJ, Gladue RP.

Cytokine. 2002 May 21;18(4):184-90.

PMID:
12126640

Supplemental Content

Loading ...
Support Center